TD Cowen Reiterates “Hold” Rating for Fusion Pharmaceuticals (NASDAQ:FUSN)

TD Cowen restated their hold rating on shares of Fusion Pharmaceuticals (NASDAQ:FUSN) in a research note issued to investors on Tuesday, Benzinga reports.

FUSN has been the subject of a number of other research reports. Brookline Capital Management downgraded shares of Fusion Pharmaceuticals from a buy rating to a hold rating in a research report on Tuesday, March 19th. SVB Leerink reaffirmed a market perform rating and issued a $21.00 price target (up previously from $17.00) on shares of Fusion Pharmaceuticals in a report on Tuesday, March 19th. Jefferies Financial Group reiterated a hold rating and set a $21.00 price target (up previously from $10.00) on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Raymond James restated a market perform rating on shares of Fusion Pharmaceuticals in a research report on Tuesday, March 19th. Finally, Leerink Partnrs downgraded Fusion Pharmaceuticals from an outperform rating to a market perform rating in a research note on Tuesday, March 19th. Thirteen research analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of Hold and a consensus target price of $20.25.

Fusion Pharmaceuticals Trading Up 0.0 %

Shares of NASDAQ:FUSN opened at $21.26 on Tuesday. The company has a current ratio of 15.01, a quick ratio of 15.01 and a debt-to-equity ratio of 0.16. Fusion Pharmaceuticals has a 12-month low of $2.31 and a 12-month high of $21.55. The business has a 50 day moving average of $16.06 and a two-hundred day moving average of $9.84. The company has a market capitalization of $1.80 billion, a PE ratio of -14.46 and a beta of -0.72.

Fusion Pharmaceuticals (NASDAQ:FUSN) last posted its earnings results on Wednesday, March 20th. The company reported ($0.39) earnings per share for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Fusion Pharmaceuticals had a negative net margin of 4,136.55% and a negative return on equity of 46.59%. As a group, analysts forecast that Fusion Pharmaceuticals will post -1.46 EPS for the current year.

Institutional Trading of Fusion Pharmaceuticals

A number of institutional investors have recently made changes to their positions in FUSN. Signaturefd LLC boosted its holdings in Fusion Pharmaceuticals by 883.0% during the 4th quarter. Signaturefd LLC now owns 2,949 shares of the company’s stock valued at $28,000 after acquiring an additional 2,649 shares during the period. Tower Research Capital LLC TRC boosted its stake in shares of Fusion Pharmaceuticals by 2,064.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 3,008 shares of the company’s stock valued at $29,000 after purchasing an additional 2,869 shares during the period. New York State Common Retirement Fund purchased a new stake in Fusion Pharmaceuticals during the 4th quarter worth approximately $64,000. China Universal Asset Management Co. Ltd. acquired a new position in shares of Fusion Pharmaceuticals in the fourth quarter worth $80,000. Finally, Envestnet Asset Management Inc. purchased a new stake in shares of Fusion Pharmaceuticals during the fourth quarter worth $110,000. 72.85% of the stock is owned by institutional investors and hedge funds.

Fusion Pharmaceuticals Company Profile

Fusion Pharmaceuticals Inc, a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines in Canada and the United States. The company's lead product candidates include FPI-2265 that is in Phase 2 clinical trial to treat prostate-specific membrane antigens; and FPI-1434 that is in Phase 1 clinical trial as a monotherapy in patients with solid tumors expressing that target insulin-like growth factor 1 receptor.